Product image of Kylnetta Ed (Drospirenone, Ethinylestradiol | Lactose Anhydrous) supplied by GNH India

Kylnetta Ed

Active Ingredient:
Drospirenone, Ethinylestradiol | Lactose Anhydrous
Origin:
EU

Kylnetta Ed (Drospirenone, Ethinylestradiol | Lactose Anhydrous)

Drospirenone/Ethinylestradiol, the active ingredient in Kylnetta Ed, is a combined oral contraceptive presented as an oral tablet for oral use. It prevents pregnancy and is indicated for women of reproductive age seeking reliable hormonal birth control.
GNH India supplies Kylnetta Ed as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Gedeon Richter Plc.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Kylnetta Ed is a combined hormonal contraceptive that acts on the reproductive endocrine system to prevent pregnancy.

  • Contraception: prevents unintended pregnancy by inhibiting ovulation.
  • Menstrual cycle regulation: helps achieve more predictable menstrual bleeding patterns.
  • Acne management: may improve mild to moderate acne associated with hormonal fluctuations.

How It Works

  • Drospirenone/Ethinylestradiol works by suppressing the hypothalamic‑pituitary‑gonadal axis, inhibiting the surge of luteinising hormone (LH) and follicle‑stimulating hormone (FSH) required for ovulation. The progestogenic component also thickens cervical mucus and alters the endometrial lining, creating an environment unsuitable for sperm penetration and implantation.

Side Effects

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Breast tenderness: discomfort or swelling of breast tissue.
  • Headache: occasional throbbing or pressure sensation.
  • Spotting or breakthrough bleeding: irregular light bleeding between periods.
  • Weight gain: modest increase in body weight.
  • Mood changes: fluctuations in mood or irritability.

Serious or Rare Side Effects

  • Venous thromboembolism: deep vein thrombosis or pulmonary embolism.
  • Arterial thrombosis: stroke or myocardial infarction.
  • Severe hypertension: sudden increase in blood pressure.
  • Liver dysfunction: jaundice or abnormal liver enzymes.
  • Allergic reaction: rash, swelling, or anaphylaxis.
  • Gallbladder disease: inflammation or stones.

Precautions & Warnings

Kylnetta Ed requires careful assessment before use to minimise risks.

  • Cardiovascular risk assessment: evaluate history of thrombosis or clotting disorders.
  • Liver function screening: avoid in active liver disease.
  • Smoking status: contraindicated in women over 35 who smoke.
  • Pregnancy avoidance: do not use if pregnant or planning pregnancy without contraception.
  • Blood pressure monitoring: check regularly during therapy.
  • Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Avoid Interactions

Kylnetta Ed can interact with several medicines that affect hormone metabolism or clotting risk.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin): may markedly reduce contraceptive effectiveness.
  • Anticoagulants (e.g., warfarin): combined use can increase the risk of thrombotic events.

Moderate Interactions (Monitor Closely)

  • Antifungal agents (e.g., ketoconazole, itraconazole): may increase hormone levels, raising side‑effect potential.
  • Antiretroviral drugs (e.g., efavirenz): may lower contraceptive efficacy.
  • Herbal supplements containing St. John’s wort: may diminish hormone concentrations.

Frequently Asked Questions

Kylnetta Ed is a combined oral contraceptive containing drospirenone and ethinylestradiol. It is prescribed to prevent unintended pregnancy in women of reproductive age by inhibiting ovulation and creating cervical mucus conditions that block sperm entry.

The combination suppresses the release of luteinising hormone and follicle‑stimulating hormone from the pituitary, preventing the ovulatory surge. Drospirenone also thickens cervical mucus and alters the endometrium, making implantation unlikely.

The dosing regimen for Kylnetta Ed is determined by the prescribing healthcare professional. Typically, it is taken as a daily oral tablet following the schedule indicated on the prescription label.

Kylnetta Ed is contraindicated during pregnancy because it is designed to prevent conception. Women who become pregnant should discontinue use. Limited data are available for breastfeeding; the prescriber should evaluate risks and benefits before use.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kylnetta Ed contains drospirenone, a progestin with anti‑mineralocorticoid activity, which may reduce water retention compared with some other progestins. Its efficacy in preventing pregnancy is comparable to other combined pills, while the side‑effect profile may differ slightly based on the progestin component.

Kylnetta Ed tablets should be stored at room temperature, below 25 °C, in their original blister pack. Protect them from excess moisture and direct sunlight to maintain potency throughout the shelf life.

Kylnetta Ed is taken orally, once daily, at the same time each day. The tablet is swallowed whole with water and should be started according to the prescriber’s instructions, usually on the first day of the menstrual cycle or after a hormone‑free interval.

The most serious risks include venous or arterial thromboembolism, such as deep‑vein thrombosis, pulmonary embolism, stroke, or myocardial infarction. Additional serious concerns are severe hypertension, liver disease, and rare allergic reactions. Prompt medical attention is required if symptoms of these conditions appear.

Kylnetta Ed is contraindicated in women with a history of thromboembolic disorders, active liver disease, known or suspected breast cancer, uncontrolled hypertension, or those who are pregnant. It should also be avoided by smokers over 35 years of age and individuals taking medications that strongly induce CYP3A4 enzymes.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Drospirenone, Ethinylestradiol | Lactose Anhydrous

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT